Recent findings regarding the role of AR in breast cancer [7, 12–17] suggest that estimating AR activity may have clinical utility since trials with both Enzalutamide and Enobosarm [48] showed efficacy in metastatic ER + disease resistant to other endocrine and chemotherapy treatments. Here, AR is linked to glycogen storage disease VI.